Zacks: Brokerages Set $2.27 Target Price for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM)

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price target of $2.27 for the company and are expecting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given Zomedica Pharmaceuticals Corp (NYSEAMERICAN) an industry rank of 74 out of 256 based on the ratings given to related companies.

Separately, HC Wainwright reissued a “buy” rating on shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in a report on Wednesday, June 5th.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc increased its holdings in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6.1% in the third quarter. Vanguard Group Inc now owns 145,747 shares of the company’s stock valued at $273,000 after buying an additional 8,381 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% during the 4th quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock worth $168,000 after purchasing an additional 16,065 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 56.5% during the 4th quarter. Rhumbline Advisers now owns 46,410 shares of the company’s stock worth $57,000 after purchasing an additional 16,750 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 2.3% during the 4th quarter. BlackRock Inc. now owns 1,767,342 shares of the company’s stock worth $2,173,000 after purchasing an additional 40,244 shares in the last quarter. 14.64% of the stock is owned by institutional investors.

NYSE ZOM traded down $0.01 during trading hours on Friday, hitting $0.26. 6,381 shares of the stock were exchanged, compared to its average volume of 123,688. The stock has a market capitalization of $26.48 million, a P/E ratio of -1.48 and a beta of 0.80. Zomedica Pharmaceuticals Corp has a 12-month low of $0.20 and a 12-month high of $2.98.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.12) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Zomedica Pharmaceuticals Corp will post -0.26 earnings per share for the current year.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Featured Story: How to Use a Moving Average for Trading 

Get a free copy of the Zacks research report on Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.